Novel therapies for the treatment of non-small cell lung cancer.
The management of advanced NSCLC remains a daunting challenge. However, new tools are available for treating this malignancy and continued progress is likely. The future is bright with a myriad of opportunities to exploit our ever-expanding knowledge of tumor biology. What is perhaps most needed, however, is development of new methods to prevent children and young adults from ever taking up the use of tobacco. In addition, we need new techniques to assist those who are already addicted to escape from tobacco's death grip. Sadly, most users of tobacco still fail to recognize the dangers of their habit. This needs to change!
Johnson
David H
DH
Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 777 Preston Research Building, Nashville, TN 37232-6307, USA. david.johnson@mcmail.vanderbilt.edu
Schiller
Joan H
JH
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D003131:Combined Modality Therapy; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D061965:Matrix Metalloproteinase Inhibitors; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D061965:Matrix Metalloproteinase Inhibitors; D016376:Oligonucleotides, Antisense